Hannover Rück SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HVRRF research report →
Price Chart
About the company
Hannover Rück SE, along with its group entities, offers a broad spectrum of reinsurance products and services worldwide. Operations are structured around two principal segments: Property & Casualty Reinsurance, and Life & Health Reinsurance. Within Property & Casualty Reinsurance, its offerings span traditional property and casualty coverage, facultative arrangements, extensive catastrophe excess-of-loss protection, custom-tailored structured reinsurance, and innovative insurance-linked securities.
- CEO
- Clemens Jungsthofel
- IPO
- 2009
- Employees
- 4,078
- HQ
- Hanover, NI, DE
Get TickerSpark's AI analysis on HVRRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.80B
- P/E
- 12.77
- Fwd P/E
- 13.08
- PEG
- 1.02
- P/S
- 1.22
- P/B
- 2.59
- EV/EBITDA
- 9.81
- Div Yield
- 4.25%
- Gross Margin
- 29.81%
- Op Margin
- 13.15%
- Net Margin
- 9.53%
- ROE
- 20.68%
- ROIC
- 3.92%
Latest fiscal year · YoY change
- Revenue
- $24.02B+804.5%
- Gross Profit
- $22.87B+804.3%
- Op Income
- $3.41B
- Net Income
- $2.64B+13.3%
- EPS
- $21.88+13.3%
- OCF Growth
- +0.1%
- FCF Growth
- +0.1%
- 52W High
- $330.00
- 52W Low
- $262.33
- 50D MA
- $304.04
- 200D MA
- $294.98
- Beta
- 0.12
- RSI (14)
- 100
- Avg Volume
- 4
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hannover Re said 9M 2026 results were strong across P&C and Life & Health, with group net income of EUR 2.1 billion, a 83.7% P&C combined ratio, and management saying it is well on track to meet full-year targets.· November 9, 2026
- Group net income was EUR 2.1 billion in the first 9 months of 2026, and management said it is on track to meet the full-year target.
- P&C reinsurance combined ratio was 83.7%, comfortably inside the sub-87% target range, despite booking the full large-loss budget.
- Large losses came in EUR 470 million below budget, but management used the room to add reserve resiliency and strengthen the balance sheet.
- Life & Health reinsurance service result was EUR 717 million, with new business CSM of EUR 503 million and management saying it remains on track for its full-year target.
- Return on investment was 3.7%, above the 3.5% target, and solvency remained strong at 242% even after higher capital requirements.
Reported 9M 2026 group net income was EUR 2.1 billion. P&C reinsurance posted a combined ratio of 83.7%, and management said large losses were EUR 470 million below budget, though the full budget was booked. Life & Health reinsurance service result was EUR 717 million, and new business CSM was EUR 503 million. Return on investment was 3.7% versus a 3.5% target, solvency was 242%, operating capital generation was around EUR 2.1 billion, and capital requirements increased by around EUR 1 billion. Management said the lower end of the 2026 P&C growth target remains within reach, the Life & Health full-year target of around EUR 925 million remains on track, and the company maintained current-year guidance while saying earnings could land ahead of target if benign losses and investment performance continue.
Clemens Jungsthofel characterized the quarter as very strong, with “underlying profitability” strong in both business groups and the balance sheet further strengthened. He emphasized that benign losses and strong investment performance give Hannover Re flexibility to add reserve resiliency or realize hidden losses and reinvest at higher yields. His tone was confident but measured: the company is on track for 2026, while the detailed 2027 outlook will come at Investors Day.
Christian Hermelingmeier focused on the quality of the P&C book and said the 83.7% combined ratio included a material increase in reserve resiliency, making underlying profitability even better than reported. He noted large losses were EUR 470 million below budget, EBIT increased by 20%, the currency result was minus EUR 40 million in P&C and minus EUR 52 million in Life & Health, and the return on investment was 3.7%, comfortably above target. He also said reinvestment yield at quarter-end was around 5% and the book yield was around 3.8%, while capital requirements rose by around EUR 1 billion as a sign of profitable growth and capital deployment.
Analysts focused on the year-on-year decline in new business CSM, the path to the lower end of the P&C growth target, and the jump in capital requirements. Management said the main pressure on CSM came from rate decreases across the traditional P&C book, estimated at roughly 2 percentage points on combined ratio impact, while volume actually grew 7% in traditional P&C. On solvency and growth, management said the higher capital need reflects profitable growth, higher assets under management, and planning for future nat cat capacity, but detailed 2027 guidance will only be given at Investors Day. In Life & Health, management said the Q3 assumption updates in morbidity and mortality were prudent, mainly in APAC morbidity, and explicitly rejected the idea of a negative trend.
The bull case from this call is that Hannover Re is still growing while keeping profitability high: P&C revenue momentum improved in Q3, combined ratio stayed well below target, and new business CSM remained strong at EUR 2.3 billion in P&C and EUR 503 million in Life & Health. Management also sounded confident that benign large losses and strong investment income can support additional balance sheet strength or earnings upside. The company said it remains well on track for 2026 and could land ahead of targets if current conditions hold.
The main risks flagged on the call are softer P&C market conditions, especially rate pressure and higher competition, which are already weighing on reported top-line growth and new business CSM. Management also pointed to higher capital requirements, assumption updates in Life & Health morbidity and mortality, and specific losses such as the Colombia earthquake and credit exposures that were booked prudently. They cautioned that the Q3 solvency and growth mix is hard to extrapolate and deferred detailed 2027 guidance to Investors Day.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 49.8%
- Shares Outstanding
- 120.60M
- Float Shares
- 60.03M
Held by 25 ETFs
Biggest fund positions in HVRRF by dollar value.
Our HVRRF coverage
Recent articles, reports, and earnings notes.
No research on HVRRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HVRRF report →Hannover Re Posts Higher Net Profit on Below-Budget Large Losses
wsj.com · Nov 9
Hannover Rück (OTC:HVRRF) Stock Price Down 2.5% – Here’s What Happened
defenseworld.net · Nov 4
Hannover Rück SE (HVRRF) Q4 2024 Earnings Conference Call Transcript
seekingalpha.com · Mar 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.